for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Genmab Announces U.S. FDA Approval Of Subcutaneous Formulation Of Daratumumab, Darzalex Faspro For The Treatment Of Patients With Multiple Myeloma

May 1 (Reuters) - Genmab A/S:

* GENMAB ANNOUNCES U.S. FDA APPROVAL OF SUBCUTANEOUS FORMULATION OF DARATUMUMAB, DARZALEX FASPRO™ (DARATUMUMAB AND HYALURONIDASE-FIHJ), FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

* GENMAB A/S - SUBCUTANEOUS FORMULATION OF DARATUMUMAB, DARZALEX FASPRO™, APPROVED BY U.S. FDA FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up